Division of Hematology, Oncology, Immunology, and Rheumatology:
Department of Pediatrics
Children's Oncology Group Trials
Children’s Oncology Group Studies (COG)
Unless stated otherwise, Dr. Ray Tannous is the PI for all of the following
protocols. For information regarding these studies, Contact Ray Tannous, MD or Marsha Gerot
PEDIATRICS-COG
Biological Studies
AEWS02B1: A Groupwide Biology and Banking Study for Ewing's Sarcoma
AALL03B1: Classification of Acute Lymphoblastic Leukemia (for subjects less than 31 years of age)
P9851: Osteosarcoma Biology Studies
ANBL00B1: Neuroblastoma Biology Studies
D9902 IRSD: A Group-Wide Protocol for Collecting and Banking Research Specimens
ABTR01B1: A Childrens' Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
Brian Tumors
ANCS02B3: A Children's Oncology Group Protocol for Collecting and Banking Brain Tumor Research Specimens
ACNS0423: A Phase II Study of Concurrent Radiation and Temozolomide Followed by Temozolomide and Lomustine (CCNU) in the Treatment of Children with High Grade Glioma (PI: Raymond Tannous) Contact Marsha Gerot
Leukemia: ALL
ALTE02C2: Neurobehavioral Outcomes in Childhood Acute Lymphoblastic Leukemia
AALL0331: Standard Risk B-Precursor Acute Lymphoblastic Leukemia (PI: Raymond Tannous) Contact Marsha Gerot
AALL02P2: Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CRI > 18 months)
Lymphomas
ANHL0131: A Phase III Study of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Adriamycin, Predisone, Vincristine) Versus Consolidation with Regimen Including Vinblastine
A5971: A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lmphoblastic Lymphoma or Localized Lmphoblastic Lymphoma
Hodgkin's Lymphoma
AHOD0031: A Phase III Group-Wide Study of Dose Intensive, Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin's Disease
Medulloblastoma
ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma - A Phase III, Double Randomized Trial
Nephroblastoma (Wilmas')
4941L National Wilms’ Tumor Late Effects Study. Evaluation of patients and families registered and treated on National Wilms’ Tumor Studies 1, 2, 3, 4 for late effects of disease/treatment.
Neuroblastoma
ANBL0032: A Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
COG-A3973: A Randomized Study of Purged Versus Unpurged Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma, (temporarily closed 3/3/06)
ANBL00P2: Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Group.
ANBL0421: A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma (PI: Ray Tannous) Contact Marsha Gerot
New Agent
0923: A Trial of Carboxypeptidase-G2 (CPDG2) for the Management of Patients with Intrathecal Methotrexate Overdose
Non-therapeutic
ALTE03N1: Key Adverse Events After Childhood Cancer
Rhabdomyosarcoma
ARST0331: Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide with or without Radiation therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma, (PI: Raymond Tannous), Contact Marsha Gerot
PEDIATRICS-OTHER
Brain Tumors
A Phase I, Open-Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of Octreother® (90Y-DOTA-tyr3-Octreotide) Administered by Intravenous Infusion to Children with Refractory Somatostatin-Receptor Positive Tumors (PI: Sue O’Dorisio), Contact Stacy Michael, 319-335-8966
Ewings
Whole Body MRI in the Evaluation of Pediatric Malignancies (PI: Geetika Khanna), Contact Pam Zehr, 319-353-8914
Hodgikin's Lymphoma
Whole Body MRI in the Evaluation of Pediatric Malignancies (PI: Geetika Khanna), Contact Pam Zehr, 319-353-8914
Non-Hodgikin's Lymphoma
Whole Body MRI in the Evaluation of Pediatric Malignancies (PI: Geetika Khanna), Contact Pam Zehr, 319-353-8914
Neuroblastoma
An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma (PI: Sue O'Dorisio) Contact Stacy Micheal, ARNP, 319-335-8966
Whole Body MRI in the Evaluation of Pediatric Malignancies (PI: Geetika Khanna), Contact Pam Zehr, 319-353-8914
Neuro-Oncology
Evaluations of Genes and Proteins in Neuroendocrine and Nervous System Tumors, Comprehensive Pediatric Neuro-Oncology Tumor Database (PI: Sue O’Dorisio), Contact Stacy Michael, 319-335-8966
A Phase I, Open-Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of Octreother® (90Y-DOTA-tyr3-Octreotide) Administered by Intravenous Infusion to Children with Refractory Somatostatin-Receptor Positive Tumors (PI: Sue O’Dorisio), Contact Stacy Michael, 319-335-8966
A Phase III, Multi-Center, Open-Label Study to Evaluate Safety and Efficacy of MultiHance® at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients (PI: Geetika Khana) Contact Carlie Etscheidt
Renal
AREN03B2: Renal Tumors Classification Biology and Banking
Retinoblastoma
ARET0332: A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
Rhabdomyosarcoma
Whole Body MRI in the Evaluation of Pediatric Malignancies (PI: Geetika Khanna), Contact Pam Zehr, 319-353-8914
A Phase I, Open-Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of Octreother® (90Y-DOTA-tyr3-Octreotide) Administered by Intravenous Infusion to Children with Refractory Somatostatin-Receptor Positive Tumors (PI: Sue O’Dorisio), Contact Stacy Michael, 319-335-8966
Transplant
PBMTC ONC-032: High dose temozolomide, thiotepa and carboplatin with autologous stem cell rescue (ASCR) followed by continuation therapy with 13-cis-retinoic acid in patients with recurrent/refractory malignant brain tumors (PI: Mohamed Radhi) Contact David Tatman, 319-356-4324
Collection of Peripheral Blood Stem Cells for Patients with Dyskeratosis Congenita (PI: Frederick Goldman) Contact David Tatman, 319-356-4324
PBMTC GVH0313: A Phase II Study of Pentostatin for the Treatment of High Risk or Refractory GVHD in Children (PI: Mohamed Radhi) Contact David Tatman, 319-356-4324.
Pilot Study: Feasibility study of chimerism testing following allogeneic transplant (PI: Mohamed Radhi), Contact David Tatman, 319-356-4324
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ProchymalTM (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid-Refractory Acute GVHD (PI: Frederick Goldman) Contact David Tatman, 319-356-4324
For the following protocols please contact the investigator listed:
Fabry Registry: Genzyme Corp., Dr. Thomas Loew
MPS I Registry: Genzyme Corp., Dr. Thomas Loew
Gaucher Registry: Genzyme Corp., Dr. Raymond Tannous
|
